Filing Flows › Companies › Teladoc Health › Timeline
Teladoc Health stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions+15.0% to $8.77
Teladoc Health (TDOC) stock rose 15% over the last 252 sessions, to $8.77. On the way it reported 4 quarters, its insiders filed 20 open-market trades and 8 Form 144 notices of planned sales, and the company filed 9 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 6, 2026 | Form 144 | Form 144: Carlos Nueno plans to sell $271K | −7.0% (−7.3% vs SPY) | — | — |
| Oct 28, 2026 | Earnings | Earnings: beat the EPS estimate by 36.5% | +6.5% (+6.1% vs SPY) | +32.1% (+34.1% vs SPY) | — |
| Sep 25, 2026 | 8-K | Directors and officers: departures, appointments, pay | −0.8% (−1.4% vs SPY) | −8.0% (−7.6% vs SPY) | +3.2% (+4.2% vs SPY) |
| Sep 11, 2026 | Form 144 | Form 144: Charles Divita plans to sell $109K | +1.1% (+0.3% vs SPY) | +3.1% (+2.4% vs SPY) | −5.4% (−8.4% vs SPY) |
| Sep 11, 2026 | Insider sale | Divita Charles III sold $109K | +1.1% (+0.3% vs SPY) | +3.1% (+2.4% vs SPY) | −5.4% (−8.4% vs SPY) |
| Sep 3, 2026 | Form 144 | Form 144: Fernando M. Rodrigues plans to sell $64K | +0.2% (−0.9% vs SPY) | −5.9% (−4.9% vs SPY) | −15.7% (−16.6% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Charles Divita plans to sell $115K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Carlos Nueno plans to sell $39K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Adam Vandervoort plans to sell $48K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Fernando M. Rodrigues plans to sell $34K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Form 144 | Form 144: Kelly Bliss plans to sell $46K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Insider sale | Vandervoort Adam C sold $48K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Insider sale | Nueno Carlos sold $39K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Insider sale | Divita Charles III sold $115K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Sep 2, 2026 | Insider sale | Bliss Kelly sold $46K | +3.1% (+2.7% vs SPY) | −2.6% (−2.7% vs SPY) | −9.9% (−10.5% vs SPY) |
| Aug 31, 2026 | 8-K | Directors and officers: departures, appointments, pay | −1.3% (−0.6% vs SPY) | −1.3% (−1.1% vs SPY) | −8.9% (−8.6% vs SPY) |
| Aug 13, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.2% (−2.0% vs SPY) | −7.0% (−5.0% vs SPY) | −6.9% (−4.6% vs SPY) |
| Aug 3, 2026 | 8-K | Directors and officers: departures, appointments, pay | +0.4% (−1.3% vs SPY) | +5.8% (+3.8% vs SPY) | −6.5% (−7.0% vs SPY) |
| Jul 29, 2026 | Earnings | Earnings: beat the EPS estimate by 10.8% | −1.9% (−0.4% vs SPY) | −33.3% (−37.3% vs SPY) | −39.1% (−42.5% vs SPY) |
| Jun 11, 2026 | Insider sale | Divita Charles III sold $125K | +3.9% (+2.2% vs SPY) | +7.7% (+5.5% vs SPY) | +31.7% (+28.2% vs SPY) |
| Jun 2, 2026 | Insider sale | Vandervoort Adam C sold $60K | −4.8% (−4.9% vs SPY) | −11.1% (−8.5% vs SPY) | +14.0% (+15.4% vs SPY) |
| Jun 2, 2026 | Insider sale | Rodrigues Fernando M. sold $43K | −4.8% (−4.9% vs SPY) | −11.1% (−8.5% vs SPY) | +14.0% (+15.4% vs SPY) |
| Jun 2, 2026 | Insider sale | Nueno Carlos sold $47K | −4.8% (−4.9% vs SPY) | −11.1% (−8.5% vs SPY) | +14.0% (+15.4% vs SPY) |
| Jun 2, 2026 | Insider sale | Divita Charles III sold $146K | −4.8% (−4.9% vs SPY) | −11.1% (−8.5% vs SPY) | +14.0% (+15.4% vs SPY) |
| Jun 2, 2026 | Insider sale | Bliss Kelly sold $59K | −4.8% (−4.9% vs SPY) | −11.1% (−8.5% vs SPY) | +14.0% (+15.4% vs SPY) |
| Apr 29, 2026 | Earnings | Earnings: beat the EPS estimate by 26.7% | −0.8% (−0.8% vs SPY) | +10.4% (+8.7% vs SPY) | +22.4% (+16.6% vs SPY) |
| Mar 30, 2026 | 8-K | Directors and officers: departures, appointments, pay | +5.9% (+3.0% vs SPY) | +3.4% (−0.8% vs SPY) | +14.6% (+2.8% vs SPY) |
| Mar 11, 2026 | Insider sale | Divita Charles III sold $152K | −1.8% (−1.7% vs SPY) | +0.7% (+1.7% vs SPY) | −5.9% (−6.6% vs SPY) |
| Mar 2, 2026 | Insider sale | Vandervoort Adam C sold $139K | −1.9% (−2.0% vs SPY) | −3.5% (−1.5% vs SPY) | −2.3% (+5.6% vs SPY) |
| Mar 2, 2026 | Insider sale | Nueno Carlos sold $103K | −1.9% (−2.0% vs SPY) | −3.5% (−1.5% vs SPY) | −2.3% (+5.6% vs SPY) |
| Mar 2, 2026 | Insider sale | Divita Charles III sold $257K | −1.9% (−2.0% vs SPY) | −3.5% (−1.5% vs SPY) | −2.3% (+5.6% vs SPY) |
| Mar 2, 2026 | Insider sale | Bliss Kelly sold $136K | −1.9% (−2.0% vs SPY) | −3.5% (−1.5% vs SPY) | −2.3% (+5.6% vs SPY) |
| Feb 25, 2026 | Earnings | Earnings: beat the EPS estimate by 52.1% | +2.4% (+1.6% vs SPY) | +11.6% (+12.7% vs SPY) | +20.4% (+24.7% vs SPY) |
| Feb 18, 2026 | 8-K | Directors and officers: departures, appointments, pay | +4.6% (+4.9% vs SPY) | −0.2% (−1.2% vs SPY) | +16.9% (+20.9% vs SPY) |
| Feb 12, 2026 | 8-K | Directors and officers: departures, appointments, pay | +4.0% (+3.9% vs SPY) | +5.9% (+4.7% vs SPY) | +18.7% (+20.6% vs SPY) |
| Dec 16, 2025 | 8-K | Directors and officers: departures, appointments, pay | −2.2% (−1.1% vs SPY) | −2.7% (−4.4% vs SPY) | −16.5% (−18.7% vs SPY) |
| Dec 12, 2025 | 8-K | Directors and officers: departures, appointments, pay | −2.8% (−2.7% vs SPY) | −4.3% (−4.4% vs SPY) | −13.3% (−14.8% vs SPY) |
| Dec 11, 2025 | Insider sale | Divita Charles III sold $131K | −0.9% (−1.1% vs SPY) | −5.9% (−3.5% vs SPY) | −5.9% (−7.3% vs SPY) |
| Dec 2, 2025 | Insider sale | Vandervoort Adam C sold $43K | +0.8% (+0.6% vs SPY) | +1.6% (+1.1% vs SPY) | −6.1% (−6.6% vs SPY) |
| Dec 2, 2025 | Insider sale | Nueno Carlos sold $29K | +0.8% (+0.6% vs SPY) | +1.6% (+1.1% vs SPY) | −6.1% (−6.6% vs SPY) |
| Dec 2, 2025 | Insider sale | Bliss Kelly sold $34K | +0.8% (+0.6% vs SPY) | +1.6% (+1.1% vs SPY) | −6.1% (−6.6% vs SPY) |
Insiders’ record here
In the year on the chart, Teladoc Health's insiders reported 0 open-market buys ($0) and 20 sales ($1.9M). Of the 15 old enough to score, 10 were followed by the stock doing what the trade implied over the next 63 sessions (beating SPY after a buy, lagging it after a sale); the median excess return after a buy was — and after a sale −17.3%.
Across the whole universe (19,782 scored trades), insider buys beat the market 46% of the time and sales were followed by a lagging stock 61% of the time; buys of $1M or more 39%. Every pattern →
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Teladoc Health: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.